# FLI1

## Overview
FLI1 is a gene that encodes the Fli-1 proto-oncogene, an ETS transcription factor, which plays a pivotal role in regulating gene expression involved in cell proliferation, differentiation, and oncogenesis. The Fli-1 protein is characterized by its ETS DNA-binding domain, which facilitates the recognition of specific DNA sequences, and a Pointed (PNT) domain that mediates protein-protein interactions. As a transcription factor, Fli-1 is integral to various cellular processes, including hematopoiesis and megakaryocyte development, through its interactions with other transcription factors such as GATA-1 and RUNX-1 (van2005FLI1; Eisbacher2003ProteinProtein). Clinically, aberrations in FLI1 expression or function are implicated in several diseases, including Ewing's sarcoma, where the EWS-FLI1 fusion protein acts as an oncogenic driver, and autoimmune disorders like systemic lupus erythematosus (Mikhailova2023Fli1; Li2014The). The gene's involvement in these pathologies underscores its potential as a target for therapeutic interventions.

## Structure
FLI1, a member of the ETS family of transcription factors, is characterized by a conserved ETS DNA-binding domain. This domain is composed of a winged helix-turn-helix motif, which includes three alpha helices and four anti-parallel beta sheets, allowing it to recognize specific DNA sequences known as ETS binding sites (Kar2013Molecular). The protein also contains a Pointed (PNT) domain, which is involved in protein-protein interactions and transcriptional repression (Kar2013Molecular).

The EWS-FLI1 fusion protein, associated with Ewing sarcoma, results from the translocation of the FLI1 gene to chromosome 22, fusing the EWS gene's amino-terminal region with the FLI1 gene's carboxyl-terminal DNA binding domain. This fusion protein is intrinsically disordered outside the ETS domain and relies on sequence composition for its transactivation function (Kar2013Molecular; Uversky2014Pathological).

Post-translational modifications of FLI1, such as acetylation, play a role in regulating its function, affecting DNA binding, protein stability, and transcriptional potency (Kar2013Molecular). The protein's interactions with other transcription factors and proteins, such as RNA polymerase II and CREB binding protein, are crucial for its role in oncogenesis (Kar2013Molecular).

## Function


## Clinical Significance
The FLI1 gene is implicated in various diseases due to its role in regulating cell proliferation and differentiation. Overexpression of FLI1 is associated with several cancers, including Ewing's sarcoma, where it forms an oncogenic fusion protein EWS-FLI1 through chromosomal translocation, leading to malignant transformation and tumor growth (Mikhailova2023Fli1). In hematological malignancies, FLI1 overexpression is linked to erythroleukemia and acute myeloid leukemia (AML), where it inhibits differentiation and promotes proliferation (Li2014The). FLI1 gene amplification has also been identified in diffuse large B-cell lymphomas (Li2014The).

In autoimmune diseases, FLI1 overexpression is noted in systemic lupus erythematosus (SLE), contributing to increased antibody production and renal pathology (Li2014The). Conversely, FLI1 downregulation is associated with systemic sclerosis (SSc), where it contributes to fibrosis and vasculopathy (Mikhailova2023Fli1). Mutations in FLI1 are linked to bleeding disorders, such as Paris-Trousseau thrombocytopenia, characterized by thrombocytopenia and platelet defects (Stevenson2015ParisTrousseau; Stockley2013Enrichment). These mutations can lead to excessive bleeding and platelet secretion defects (Stockley2013Enrichment). FLI1's role in these conditions highlights its clinical significance as a potential target for therapeutic intervention.

## Interactions
FLI1, a member of the ETS family of transcription factors, engages in various protein-protein interactions that are crucial for its function in cellular processes. It interacts directly with ARIP3, a member of the PIAS E3 SUMO ligase family, through its ETS domain and the SAP domain of ARIP3. This interaction is essential for ARIP3's ability to repress FLI1-mediated transactivation without affecting FLI1's DNA-binding activity (van2005FLI1). FLI1 is also sumoylated by Ubc9, a SUMO-conjugating enzyme, and this modification is enhanced by PIASxα and PIASxβ, which facilitate the conjugation of SUMO to FLI1 at lysine 67 (van2005FLI1).

FLI1 forms multiprotein complexes with other transcription factors such as GATA-1 and RUNX-1, which are important for megakaryocyte development. The interaction with GATA-1 is mediated by the ETS domain of FLI1 and the zinc fingers of GATA-1, enhancing GATA-1's DNA-binding and transactivation capabilities (Eisbacher2003ProteinProtein). FLI1 also interacts with RUNX-1, and this interaction is modulated by post-translational modifications like dephosphorylation at Ser10, which enhances their binding during megakaryocyte differentiation (Huang2009DifferentiationDependent). These interactions highlight FLI1's role in transcriptional regulation and its involvement in hematopoiesis and oncogenesis.


## References


[1. (Uversky2014Pathological) Vladimir N. Uversky, Vrushank Davé, Lilia M. Iakoucheva, Prerna Malaney, Steven J. Metallo, Ravi Ramesh Pathak, and Andreas C. Joerger. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chemical Reviews, 114(13):6844–6879, May 2014. URL: http://dx.doi.org/10.1021/cr400713r, doi:10.1021/cr400713r. This article has 223 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/cr400713r)

[2. (Mikhailova2023Fli1) Elena V. Mikhailova, Irina V. Romanova, Alexei Y. Bagrov, and Natalia I. Agalakova. Fli1 and tissue fibrosis in various diseases. International Journal of Molecular Sciences, 24(3):1881, January 2023. URL: http://dx.doi.org/10.3390/ijms24031881, doi:10.3390/ijms24031881. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24031881)

[3. (Stevenson2015ParisTrousseau) William S. Stevenson, David J. Rabbolini, Lucinda Beutler, Qiang Chen, Sara Gabrielli, Joel P. Mackay, Timothy A. Brighton, Christopher M. Ward, and Marie-Christine Morel-Kopp. Paris-trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a dna-binding domain mutation in fli1. Blood, 126(17):2027–2030, October 2015. URL: http://dx.doi.org/10.1182/blood-2015-06-650887, doi:10.1182/blood-2015-06-650887. This article has 59 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2015-06-650887)

[4. (Stockley2013Enrichment) Jacqueline Stockley, Neil V. Morgan, Danai Bem, Gillian C. Lowe, Marie Lordkipanidzé, Ban Dawood, Michael A. Simpson, Kirsty Macfarlane, Kevin Horner, Vincenzo C. Leo, Katherine Talks, Jayashree Motwani, Jonathan T. Wilde, Peter W. Collins, Michael Makris, Steve P. Watson, and Martina E. Daly. Enrichment of fli1 and runx1 mutations in families with excessive bleeding and platelet dense granule secretion defects. Blood, 122(25):4090–4093, December 2013. URL: http://dx.doi.org/10.1182/blood-2013-06-506873, doi:10.1182/blood-2013-06-506873. This article has 98 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2013-06-506873)

[5. (van2005FLI1) Emile van den Akker, Sabine Ano, Hsiu-Ming Shih, Ling-Chi Wang, Martine Pironin, Jorma J. Palvimo, Noora Kotaja, Olivier Kirsh, Anne Dejean, and Jacques Ghysdael. Fli-1 functionally interacts with piasxα, a member of the pias e3 sumo ligase family. Journal of Biological Chemistry, 280(45):38035–38046, November 2005. URL: http://dx.doi.org/10.1074/jbc.M502938200, doi:10.1074/jbc.m502938200. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M502938200)

[6. (Kar2013Molecular) Adwitiya Kar and Arthur Gutierrez-Hartmann. Molecular mechanisms of ets transcription factor-mediated tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 48(6):522–543, September 2013. URL: http://dx.doi.org/10.3109/10409238.2013.838202, doi:10.3109/10409238.2013.838202. This article has 150 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/10409238.2013.838202)

[7. (Huang2009DifferentiationDependent) Hui Huang, Ming Yu, Thomas E. Akie, Tyler B. Moran, Andrew J. Woo, Nathan Tu, Zachary Waldon, Yin Yin Lin, Hanno Steen, and Alan B. Cantor. Differentiation-dependent interactions between runx-1 and fli-1 during megakaryocyte development. Molecular and Cellular Biology, 29(15):4103–4115, August 2009. URL: http://dx.doi.org/10.1128/mcb.00090-09, doi:10.1128/mcb.00090-09. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00090-09)

[8. (Li2014The) Y Li, H Luo, T Liu, E Zacksenhaus, and Y Ben-David. The ets transcription factor fli-1 in development, cancer and disease. Oncogene, 34(16):2022–2031, June 2014. URL: http://dx.doi.org/10.1038/onc.2014.162, doi:10.1038/onc.2014.162. This article has 131 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2014.162)

[9. (Eisbacher2003ProteinProtein) Michael Eisbacher, Melissa L. Holmes, Anthea Newton, Philip J. Hogg, Levon M. Khachigian, Merlin Crossley, and Beng H. Chong. Protein-protein interaction between fli-1 and gata-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative dna binding. Molecular and Cellular Biology, 23(10):3427–3441, May 2003. URL: http://dx.doi.org/10.1128/MCB.23.10.3427-3441.2003, doi:10.1128/mcb.23.10.3427-3441.2003. This article has 157 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/MCB.23.10.3427-3441.2003)